Media headlines about USANA Health Sciences (NYSE:USNA) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. USANA Health Sciences earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave news articles about the company an impact score of 47.3436003243291 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:

Several analysts have recently weighed in on the stock. BidaskClub upgraded shares of USANA Health Sciences from a “hold” rating to a “buy” rating in a research report on Tuesday, June 13th. Pivotal Research lowered their price objective on shares of USANA Health Sciences from $75.00 to $70.00 and set a “buy” rating on the stock in a research report on Wednesday, July 26th.

USANA Health Sciences (NYSE:USNA) traded up 1.29% during mid-day trading on Friday, hitting $58.80. 120,279 shares of the stock traded hands. The company’s 50 day moving average is $61.41 and its 200 day moving average is $60.57. The company has a market cap of $1.44 billion, a P/E ratio of 15.27 and a beta of 1.10. USANA Health Sciences has a 12 month low of $52.55 and a 12 month high of $150.00.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, July 25th. The company reported $0.98 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.06 by $0.08. USANA Health Sciences had a return on equity of 28.93% and a net margin of 9.47%. The company had revenue of $257.10 million for the quarter, compared to the consensus estimate of $273.61 million. During the same quarter in the prior year, the company posted $2.07 EPS. USANA Health Sciences’s revenue was down .5% compared to the same quarter last year. On average, analysts expect that USANA Health Sciences will post $3.79 earnings per share for the current fiscal year.

USANA Health Sciences declared that its Board of Directors has authorized a share buyback program on Tuesday, July 25th that authorizes the company to buyback $64.60 million in shares. This buyback authorization authorizes the company to buy up to 46% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s board believes its shares are undervalued.

In other USANA Health Sciences news, Director Myron W. Wentz sold 40,000 shares of the stock in a transaction on Friday, June 2nd. The shares were sold at an average price of $64.99, for a total transaction of $2,599,600.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Global Ltd Gull sold 25,467 shares of the stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $56.52, for a total transaction of $1,439,394.84. Following the transaction, the insider now owns 12,352,753 shares of the company’s stock, valued at approximately $698,177,599.56. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 171,334 shares of company stock valued at $10,413,675. 53.20% of the stock is owned by company insiders.

WARNING: This story was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another website, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/08/13/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-usana-health-sciences-usna-stock-price.html.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.

Insider Buying and Selling by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Stock Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related stocks with our FREE daily email newsletter.